DNA Methylation Detection Technology Market Size to Reach USD 10,512.0 Million in 2032
The DNA Methylation Detection Technology Market size was USD 2,880.2 million in 2024 and is expected to register a revenue CAGR of 17.5% during the forecast period
21 January, 2024 – Growth in precision medicine is a key factor driving market revenue growth. DNA methylation-related genetic variation is becoming a well understood mechanism for altered medication responsiveness and disease risk. These new insights must be integrated into the practice of customized medicine. Precision medicine principles have enabled breakthroughs in cancer therapy and are set to drastically modify the treatment of a variety of diseases, including metabolic and cardiovascular illness, autoimmune However, because DNA methylation lacks the potential to offer detailed details regarding diverse chromatin compartments, particularly tissue/cell-specific enhancer activity, it is insufficient for certain applications. Furthermore, DNA methylation is not always a repressive mark, therefore the impact on gene expression can be equivocal.
However, the revenue growth of DNA methylation detection technology market is hampered by data complexity and interpretation. DNA methylation sequencing particularly with next generation sequencing (NGS) and long read technologies, generates vast amount of data. Interpreting its data is complex due to the intricate nature of epigenetic modifications and the challenges in distinguishing biological signals from noise. The computational analysis of DNA methylation sequencing data obtained by various experimental procedures can be difficult, particularly for scientists with little experience in this area of data processing.
Key Highlights:
- Sequencing segment is expected to register the highest growth rate over the forecast period. Methylation sequencing is the process of quantifying DNA methylation using sodium bisulfite and then converting nucleotide bases. Methylation sequencing detects the methylation status of both the beginning DNA strand and the DNA methylation patterns of the resulting double-stranded DNA (post-amplification). On January 2023, GRAIL, LLC, a healthcare firm whose purpose is to detect cancer early, when it may be cured, has announced the launch of a cutting-edge research use only product for biopharmaceutical companies. The new technology solution employs GRAIL’s unique targeted methylation platform to analyse cell-free DNA (cfDNA) obtained from peripheral blood for cancer signal investigation.
- Diagnostics segment is expected to account for the largest revenue share over the forecast period. Currently, only DNA methylation appears to be a stable enough epigenetic change to be used as a biomarker in in vitro diagnostic (IVD) settings. This modification is not only stable in somatic cells and is populated to daughter cells with high fidelity, but it has also been demonstrated that DNA methylation is unaffected by clinical sample processing and storage conditions. These characteristics make disease-related methylation alterations a promising source of IVD biomarkers.
- North America accounted for largest revenue share in the DNA methylation detection technology market in 2024 driven by increase in prevalence of cancer and technological advancements. On October 2022, PacBio, a leading producer of high-quality, highly accurate sequencing technologies, has introduced the Revio long-read sequencing system, which will allow clients to significantly expand their use of PacBio’s renowned HiFi sequencing technology. Revio is supposed to allow customers to sequence up to 1,300 human entire genomes each year at 30-fold coverage for less than USD 1,000 per genome. PacBio believes that Revio’s scale and cost will enable the application of HiFi sequencing in big investigations in human genetics, cancer research, agricultural genomics, and other areas.
- Some major companies in the market report include Sysmex Corporation, Bio-Rad Laboratories, Inc., Illumina Inc., Agilent Technologies Inc., Exact Sciences Corporation, QIAGEN N.V., Abcam Limited, New England Biolabs, F. Hoffmann-La Roche Ltd, Revvity, Inc., Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Pacific Biosciences Inc., and Diagenode Diagnostics S.A.
- On January 2023, Agilent Technologies Inc. has announced the purchase of Avida Biomed, an early-stage life sciences company that creates high-performance target enrichment procedures with unique features for clinical researchers using next-generation sequencing (NGS) to investigate cancer. The acquisition strengthens Agilent’s market-leading SureSelect portfolio and accelerates the company’s goal to expand into the high-growth clinical research and diagnostics industries. Avida Biomed’s novel genomics techniques allow for simultaneous genomic and DNA methylation profiling from a single sample, without sacrificing sensitivity or specificity.
Unlock the key to transforming your business strategy with our DNA Methylation Detection Technology Market insights –
Navistrat Analytics has segmented DNA methylation detection technology market based on product, technology, application, end-use, and region:
- Product Outlook (Revenue, USD Million; 2022-2032)
- Instruments
- Software
- Consumables
- Kits and Assays
- Reagents
- Technology Outlook (Revenue, USD Million; 2022-2032)
- Microarray
- Polymerase Chain Reaction (PCR)
- Sequencing
- Methyl-CpG-Binding Domain Sequencing
- Single molecule real-time (SMRT)
- Nanopore sequencing
- Whole-Genome bisulfifite sequencing (WGBS)
- Others
- Others
- Application Outlook (Revenue, USD Million; 2022-2032)
- Clinical Research
- Diagnostics
- Gene Therapy
- Others
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Pharmaceutical & Biotechnology Companies
- Hospital & Diagnostic Laboratories
- Research & Academia
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America